Packing polymorphism of dapivirine and its impact on the performance of a dapivirine-releasing silicone elastomer vaginal ring

McCoy, C. F., Murphy, D. J., Boyd, P., Derrick, T., Spence, P., Devlin, B., & Malcolm, R. (2017). Packing polymorphism of dapivirine and its impact on the performance of a dapivirine-releasing silicone elastomer vaginal ring. *Journal of Pharmaceutical Sciences*, 106(8), 2015-2025. <https://doi.org/10.1016/j.xphs.2017.04.026>

Published in:
Journal of Pharmaceutical Sciences

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

Copyright 2017 Elsevier.

This manuscript is distributed under a Creative Commons Attribution-NonCommercial-NoDerivs License (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

1 **Packing polymorphism of dapivirine and its impact on**
2 **the performance of a dapivirine-releasing silicone**
3 **elastomer vaginal ring**

4
5 Clare F. McCoy¹, Diarmaid J. Murphy¹, Peter Boyd¹, Tiffany Derrick²,
6 Patrick Spence², Brid Devlin², R. Karl Malcolm^{1*}

7
8 ¹*School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK;*

9 ²*International Partnership for Microbicides, Silver Spring, MD 20910, USA*

10
11 *Corresponding author. Tel: +44 (0)28 9097 2319; E-mail: k.malcolm@qub.ac.uk

12
13 **Short title:** Impact of polymorphism on performance of dapivirine vaginal ring

14
15 **Keywords:** HIV microbicide; Silicone elastomer vaginal ring; Dapivirine; Formulation
16 development; Polymorphism

17
18 N.B. Red text in this document highlights changes made to the manuscript since the
19 original submission.

Abstract

A silicone elastomer vaginal ring device providing sustained release over 28 days of the antiretroviral microbicide dapivirine has recently completed Phase III clinical testing and showed moderate protection against HIV acquisition. Here, for the first time, and in support of the product licensure program, we report the impact of dapivirine packing polymorphism on the *in vitro* performance of the 25 mg dapivirine ring product. Thermal, particle size, powder x-ray diffraction and thermodynamic solubility analyses of dapivirine polymorphic forms I and IV, both of which are persistent at room temperature and with form I being the thermodynamically stable form, were conducted for micronized and non-micronized materials. Matrix-type silicone elastomer vaginal rings were manufactured and the impact of dapivirine polymorphism on key *in vitro* parameters (compression and tensile behaviour; content assay; *in vitro* release; residual content assay) was investigated. The data demonstrate that dapivirine packing polymorphism has no significant impact on *in vitro* performance of the 25 mg dapivirine vaginal ring.

1. Introduction

Many solid drug substances exist in different crystalline forms – known as packing polymorphs – that differ in their physical properties.¹ In some cases, these different crystalline forms of the drug substance can significantly affect the pharmacological performance of the drug product. One of the most widely reported examples is the influence of polymorphism on the oral bioavailability of the antiretroviral drug ritonavir.^{2,3} Ritonavir exists in two major crystalline forms – forms I and II. In 1998, the unexpected appearance of the more stable (and therefore less soluble) form II during routine testing of the drug led to compromised oral bioavailability of the drug and ultimately removal of the oral capsule formulation from the market. Since this incident, the U.S. Food and Drug Administration (FDA) has focused increased attention on the potential impact of drug polymorphism on the performance of drug products and the measures taken to ensure that physical properties do not change during shelf life. It is therefore imperative that polymorphism is investigated during the drug product development process. Both the FDA and the International Council for Harmonisation (ICH) have published regulatory documents addressing pharmaceutical polymorphism.⁴⁻⁶

Dapivirine (DPV) is an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) that is currently being developed as a vaginal microbicide for prevention of sexual transmission of human immunodeficiency virus type 1 (HIV-1).⁷⁻¹² A wide range of formulation strategies have been reported for vaginal administration of DPV,¹³⁻¹⁸ the most advanced and the most promising of which are silicone elastomer vaginal rings.¹⁹⁻³³

Two Phase III efficacy studies – The Ring Study (IPM027) and APSIRE (MTN-020) –

involving more than 4,500 women volunteers across southern and eastern Africa have recently been completed, designed to support licensure of a monthly matrix-type silicone elastomer vaginal ring containing 25 mg micronized DPV intended for 28-day continuous use (DPV Ring-004). The studies showed approximately 30% reduced incidence of HIV infection in women compared to a placebo, the first time two studies have confirmed statistically significant efficacy for a HIV microbicide.^{27,33} The lower than anticipated protection rates were attributed to poor user adherence, an ongoing problem that has adversely affected clinical testing of HIV microbicides.³³⁻⁴² Post-hoc analyses of the DPV ring clinical data in The Ring Study and ASPIRE have revealed that rates of protection are very significantly increased (>60%) in sub-groups demonstrating increased adherence.^{27,33}

Three crystalline polymorphic forms of DPV have been identified – forms I, II and IV (Figure 1).²² A dichloromethane hemi-solvate stable up to 130 °C was originally identified as polymorphic form III. However, dichloromethane is no longer used in the DPV manufacturing process. Therefore, further work with this form was no longer relevant and was not pursued. The current method for chemical synthesis of DPV reproducibly produces the drug in packing polymorphic form I, which is the most stable form at room temperature.²² To date, form I has been confirmed for all manufactured batches of micronized DPV used in clinical development²².

DPV form I undergoes a solid-solid transition to form II at ~100 °C (Figure 2; can range from 96.9 to 110.3 °C), as evidenced by a small endothermic transition in the differential scanning calorimetry (DSC) trace.^{20,23,26} The variation in solid-solid transition temperature

between form I and form II has been observed for different lots of form I; however, it could not be attributed to a single phenomenon. Upon further heating, DPV form II undergoes crystalline melting at ~220 °C (ranges from 217.9 to 226.9 °C), and then, upon cooling below 100 °C, form II instantaneously reverts to form I. Form I and form II are therefore related enantiotropically with a transition temperature close to 100 °C. The same polymorphic interconversion and crystalline melt transitions are also observed when DPV is incorporated into the silicone elastomer matrix of the Dapivirine Ring-004, indicating that there are no significant drug-polymer interactions.²³

During development, DPV has also been observed in crystalline polymorphic form IV, which is stable at room temperature and forms when dapivirine is recrystallized from methanol at higher temperatures (Figure 1). Upon heating, it exhibits two endothermic transitions at 212 and 221 °C corresponding to transformation of form IV to form II and crystalline melting of form II, respectively (Figure 1).

In order to meet the requirements of the regulatory agencies, it is important to assess how polymorphism affects drug product performance. Surprisingly, this issue seems not to have been reported – at least in the scientific literature – for other vaginal ring products, despite an explicit understanding that different polymorphic forms of a drug can exhibit significantly different solubilities in the polymeric matrix and potentially result in different drug permeation rates. Since forms I and IV are the only DPV polymorphs stable at room temperature (which is the desired storage temperature of the vaginal ring product), this

study was conducted to evaluate the thermal properties and *in vitro* performance of vaginal rings containing 25mg DPV as either the form I or the form IV polymorph.

2. Materials and methods

2.1. Materials

Non-micronized DPV form I and form IV and micronized form I were supplied by S.A. Ajinomoto OmniChem n.v. (Wetteren, Belgium). DPV form IV was micronized by JetPharma (Balerna, Switzerland). MED-4870 addition-cure silicone elastomer (Parts A and B) and MED-360 silicone oil were purchased from NuSil Technology (Carpinteria, CA, USA). Potassium dihydrogen orthophosphate, potassium hydroxide and urea (AnalaR, analytical reagent grade) were purchased from VWR International Ltd. (Dublin, Ireland). Norethindrone was purchased from LGM Pharma, (Nashville, TN, USA). HPLC-grade 2-propanol (IPA) and acetonitrile, phosphoric acid (85% w/w in water), Tween 80, sodium chloride, calcium hydroxide, bovine serum albumin, lactic acid, acetic acid and glucose were all purchased from Sigma-Aldrich (Gillingham, UK). A Millipore Direct-Q 3 UV Ultrapure Water System (Watford, UK) was used to obtain HPLC-grade water. Simulated vaginal fluid + 0.2% (w/v) Tween 80 (SVF+Tween) release media was prepared according to a previously described method followed by addition of the Tween 80 component.⁴³

2.2 Thermal analysis

The thermal stability of DPV forms I and IV were analysed by thermogravimetric analysis (TGA) using a TA Instruments Q50™ Thermogravimetric Analyser and a TA Instruments Differential Scanning Calorimeter Q20™ (TA Instruments, UK). For these experiments,

5–10 mg of sample was heated from 25 to 300 °C at 10 °C /min in an open aluminium pan under a nitrogen atmosphere. For differential scanning calorimetry (DSC) experiments, 5–7 mg of sample (either pure polymorph or 10% w/w DPV-loaded silicone elastomer) underwent heat-cool-heat cycles between 20 and 235 °C using a heating rate of 10 °C per min. The temperature range was selected to encompass the molding temperatures commonly used to fabricate DPV matrix-type rings via injection molding processes (160–180 °C). For each sample, onset temperature (°C), peak temperature (°C) and enthalpy (ΔH , J/g) values were recorded for each thermal transition observed.

2.3. Particle size analysis

The particle size distributions (PSDs) of micronized and non-micronized forms of both polymorphs were characterised using a Mastersizer 3000 (Malvern , UK) instrument fitted with an AERO S accessory. Approximately 1 g of material was weighed and added to the Venturi. Using an air pressure of 2 Bar(g), the hopper gap was sequentially raised in 0.5 mm steps from 0.5 mm and the feed rate increased to between 30 and 60% to provide a reasonable flow of powder into the instrument. The target obscuration range was 1–4 %. A minimum of six measurements of each sample were performed to give an estimate of the variability about the measurement.

2.4. Powder X-ray diffraction

Powder X-ray diffraction (PXRD) patterns of non-micronized and micronized DPV form I and IV powders were obtained using a X'PERT Pro MPR X-ray diffractometer (PANalytical Ltd., UK). Samples were pressed onto a zero background holder so that a

smooth, flat surface was achieved and mounted in a rotating sample holder. Samples were exposed to CuK α radiation (40 kV, 40 mA), scanned in continuous mode across the 2 θ angular range of 3.0–90.0° with a step size of 0.016°.

2.5. Microscopy analysis

Digital microscopy was performed using a Keyence VHX-700F series Digital Microscope (Keyence Limited, UK) fitted with an RZ 20–200x wide-range zoom lens. A small sample was dusted onto a section of adhesive tape to provide a thin layer of powder for particle morphology (shape and size) evaluation.

2.6. Ring manufacture

Matrix-type vaginal rings containing 25 mg micronized and non-micronized DPV form I or form IV dispersed in MED-4870 silicone elastomer were manufactured using a Babyplast™ 6/10P injection molding machine (Chronoplast, Spain). DPV MED-4870 Part A premixes (100 g) were prepared by accurately weighing appropriate quantities of MED-4870 (97.5% w/w), MED-360 silicone oil (2.1875% w/w) and DPV (0.3125% w/w) into a sealed polypropylene container before mixing at 3000 rpm for 3 min in a DAC-150 FVZ-K Speedmixer™ (Hauschild, Germany). Part B premixes were manufactured using the same protocol. Four 100 g portions of premix A and premix B were prepared (800 g in total) for each DPV polymorph formulation. Premixes were stored at 4 °C until use. Immediately prior to injection molding, ~100 g portions each of Part A premix and Part B premix were sequentially added to a large plastic Speedmixer™ container until ~400 g in total had been transferred. The material was handmixed for 30 s, speedmixed at 2350 rpm

for 30 s and further speedmixed for 60 s at 1800 rpm. The silicone elastomer mix was transferred to a Babyplast™ cartridge which was then fitted into the Babyplast™ injection molding machine. Rings were manufactured at 185 °C for 60 s.

2.7. Ring appearance and weight

Ring weight, colour, external diameter (ExD) and cross-sectional diameter (CSD) were recorded in order to assess the consistency of ring physical parameters. Ten rings from each DPV polymorph formulation were randomly selected and evaluated. CSD and ExD were measured using digital callipers (RS Components, UK). Care was taken not to compress the ring during measurement.

2.8. Mechanical testing

In the absence of a ratified international standard on the mechanical testing of vaginal rings, the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) have published nonbinding recommendations to industry in respect of tests for vaginal microbicide drug product specification, which include the mechanical testing of ring devices.⁴⁴ Here, as part of ongoing efforts to establish practical test methods, we have applied mechanical test methods to vaginal rings based on the minimum requirements and test methods used for reusable silicone rubber contraceptive diaphragms, as described in ISO-8009:2014.

Shore A Hardness testing, also known as durometer testing, was performed on five rings randomly selected from each DPV polymorph production run. Measurement was carried

out using a Sauter HBA 100-0 graduated dial durometer (Sauter, Switzerland) calibrated for Shore A hardness (arbitrary units). During testing the rings were placed on an unyielding, flat surface. With the durometer held in a vertical position, the instrument's indenter was pressed on the uppermost surface of the ring in a constant movement without shocks until the presser foot was parallel to the ring surface. The maximum deflection on the dial (0–100), representing the Shore Hardness was recorded. Four individual measurements per ring were recorded.

Compression testing was performed using a TA.XTplus Texture Analyser (Stable Microsystems, UK). Rings previously selected for non-destructive durometer testing were placed in the appropriate holder and analysed in compression mode using a test speed of 2 mm/s and a target distance of 5.0 mm. Six compression cycles were performed, and the last five values for the maximum compressive force exerted by the texture analyser recorded. The first value is not recorded to allow the ring to stabilize in the holder during the first compression cycle.

Tensile strength testing was also performed using the TA.XTplus Texture Analyser. Rings were placed around upper and lower tensile grips and analysed in tension mode with a test speed of 10 mm/s and a target force of 5 kg. The pass/fail criterion for tensile strength testing was set at 5 kg i.e. if the ring withstood a force equivalent to 5 kg without rupture then it was deemed acceptable.

2.9. *In vitro* release testing

Twenty-four samples of each ring formulation were selected for *in vitro* release testing over a 30-day period – twelve rings for release into a 1:1 mixture of IPA+H₂O and twelve for release into SVF+Tween. Both media have been used routinely for *in vitro* release testing of silicone elastomer vaginal rings, and other vaginal formulations, containing highly lipophilic poorly water-soluble antiretroviral microbicides, including DPV.^{17,19,20,23,25,26,31,45–47} IPA/water is commonly used as a performance test to predict and monitor the consistency in manufacturing. SVF is intended to mimic the chemical composition of vaginal fluid, including pH and osmolarity matched to normal vaginal fluid.⁴³ However, solubility of DPV in SVF is impractically low (< 1 µg/mL),^{22,46} and, as a result, *in vitro* release from vaginal rings into this medium does not correlate with *in vivo* release (as measured by residual drug content following clinical use). By comparison, use of SVF + 0.2% w/v Tween 80 closely mimics *in vivo* release,^{27,48} and its use has been supported by regulatory authorities.

On Day 0, each ring was placed into a 250 mL glass, screw-top bottle containing 200 mL of either IPA+H₂O or SVF+Tween release medium and stored in a temperature-controlled orbital shaking incubator (37°C, 60 rpm, 25 mm orbital throw). The release medium was sampled and completely replaced (100 mL) daily, with the exception of weekends where 200 mL was added. Drug release was quantified by reverse-phase HPLC with UV detection (Section 2.11).

2.10. Content assay and residual content testing

239 Both the total DPV content of manufactured rings and the residual content of rings after *in*
240 *vitro* release testing were assessed (n=6 per formulation per test). Rings were weighed and
241 then cut in half along the length of the ring. The ring halves were immediately transferred
242 into individually labelled 250 mL glass flasks containing 100 mL acetone. Flasks were
243 sealed and placed in a temperature-controlled orbital shaking incubator (37 °C, 60 rpm, 25
244 mm orbital throw). After 24 h, the flasks were removed and allowed to cool to room
245 temperature. A 1.00 mL aliquot of the acetone extraction solution was transferred to a 100
246 mL volumetric flask using a positive displacement pipette and diluted to volume with
247 methanol. Samples were allowed to stand at ambient temperature for 1 h before final
248 dilution to volume with methanol. Samples were transferred to HPLC vials and analysed
249 against standard solutions of known DPV concentration.

2.11. Solubility determination

Thermodynamic solubility of DPV (form I and form IV, micronised and non-micronised) was measured using the shake-flask method at 37 °C in both SVF+0.2% w/w Tween and 1:1 v/v IPA/water mixture. For SVF/Tween measurement, ~5 mg DPV was added to a glass vial followed by 5.00 mL SVF/Tween; for IPA/water measurement, ~40 mg DPV was added to a glass vial followed by 5.00 mL IPA/water. The sealed vials were placed in an orbital shaking incubator for 72 hr. While still in the incubator but with shaking stopped, 1.00 mL and 100 µL volumes of the saturated SVF/Tween and IPA/water solutions, respectively, were sampled from the vials using suitable micropipettes and placed in new glass vials, taking care not to sample the settled excess solid drug layer at the bottom of each vial. SVF/Tween samples were subsequently diluted twofold for HPLC analysis, while IPA/water samples were diluted by a factor of 100. Drug concentrations were subsequently quantified by HPLC. In a similar fashion, the solubilities of both DPV form I and form IV (micronized only) were measured in aqueous media at different pH values – 0.1M HCl, 0.01M HCl, pH2 (KCl/HCl), pH4 (acetate buffer), pH6 (phosphate buffer), pH8 (phosphate buffer). For each solubility measurement, the residual solids were analyzed by PXRD to determine the extent of form conversion during the solubility analysis and to ensure the results reflect the true solubility of each form.

2.12. HPLC Analysis

270 Samples for DPV content analysis in rings were analysed on a Waters HPLC system
271 (Waters Corporation, Dublin, Ireland) consisting of a 1525 Binary HPLC pump with an in-
272 line degasser AF unit, 1500 column heater, 717 Plus Autosampler and a 2487 dual
273 wavelength absorbance detector. 10 μ L of each content sample was injected onto a
274 Kromasil C18 HPLC column (150 mm x 4.6 mm, 5 μ m particle size). Column temperature
275 was maintained at 25 °C and isocratic elution was performed using a mobile phase of 75%
276 HPLC-grade methanol and 25% water with a flow rate of 0.75 mL/min and a run time of
277 15 min. DPV was detected at 257 nm after approximately 10.8 min.

278

279 *In vitro* release samples (25 μ L) were injected onto a Thermo Scientific BDS Hypersil™
280 C18 HPLC column (150 mm x 4.6 mm, 3 μ m particle size) fitted with a guard column. The
281 column was held at 45 °C and isocratic elution was performed using a mobile phase of 45%
282 HPLC-grade acetonitrile and 55% phosphate buffer (pH 3.0; 7.7 mM) with a run time of 8
283 min. DPV was detected at 240 nm after 6.1 min.

284

2.12. Statistical analyses

Where appropriate, data sets were analysed using a one-way ANOVA followed by post-hoc analysis using the Tukey-Kramer multiple comparisons test. Analysis was conducted using GraphPad Prism software and significance was noted for a P value of less than 0.05: * = significant ($0.01 < P < 0.05$), ** = very significant ($0.001 < P < 0.01$), *** = extremely significant ($P < 0.001$), ns = not significant ($P > 0.05$).

The similarity factor (f_2) – a logarithmic reciprocal square root transformation of one plus the mean squared (the average sum of squares) differences of drug percent dissolved between the test and the reference products – was calculated for ring dissolution data using Equation 1.^{49,50} The similarity factor fits the result between 0 and 100. It is 100 when the test and reference profiles are identical and tends to 0 as the dissimilarity increases. FDA and EMEA recommend that two dissolution profiles are similar when f_2 has a value between 50 and 100 following testing of at least 12 individual dosage units.

$$f_2 = 50 \times \log \left(\left[1 + \frac{1}{n} \sum_{j=1}^n |R_j - T_j|^2 \right]^{-0.5} \times 100 \right)$$

Equation 1.

3. Results and Discussion

3.1. Thermal analysis

DPV form I and form IV polymorphs were initially tested using TGA to establish their thermal stability over the range of temperatures encountered during ring manufacture via injection molding. Both polymorphs were stable up to temperatures around 240 °C, with total percent weight loss less than 0.5% at 240 °C for both polymorphic forms (data not shown). The polymorphs were then examined by DSC using a heat-cool-heat cycle between 20 and 235 °C. Representative thermograms for the non-micronized forms of DPV form I and form IV are presented in Figure 2A and 2B, respectively. Table 1 displays the mean onset peak temperature (°C), the peak maximum temperature (°C) and the enthalpy (J/g) for each transition recorded in the thermograms.

Non-micronized DPV form I, the most stable polymorphic form of the compound at room temperature and the form produced in the synthesis of DPV, displayed characteristic melting endotherms at 101 °C and 220 °C during the first heat cycle (Figure 2A), attributed to the solid-solid I→II polymorphic transformation and the form II crystalline melt, respectively.^{20,22,23} Upon cooling of this melt, an endothermic step-like shift associated with formation of amorphous DPV was observed around 80 °C. The second heat cycle then showed a glass transition (T_g) with amorphous relaxation close to 80 °C, followed by an exothermic recrystallization transition at 163 °C and the form II melt endotherm at 220 °C. Similar thermal behaviour was observed for micronized DPV form I (DSC trace not shown, but data presented in Table 1).

By comparison, the non-micronized DPV form IV showed two sharp melting endotherm transitions, one at 206 °C attributed to the solid-solid IV→II transition and the other at 220 °C due to crystalline melting of form II (Figure 2B). Micronized DPV form IV displayed a broader and smaller IV→II endothermic transition at ~190 °C compared to that observed for the non-micronized form IV material (DSC trace not shown, but data presented in Table 1), attributed to the smaller particle size of the micronized material and/or changes in crystallinity induced during the micronization process.

3.2. Particle size distribution

The PSDs of DPV form I and form II polymorphs are presented in Figure 3 for both non-micronized (nm) and micronized (m) material. The distributions were unimodal (modal particle diameters for forms I_(nm), IV_(nm), I_(m) and IV_(m) were 163, 76, 5.9 and 5.2 µm, respectively), except for an additional second smaller peak at 67 µm for the form I_(m) material. A summary of the d₉₀, d₅₀ and d₁₀ values are presented in Table 2 alongside values quoted in supplied certificates of analysis (where available). The data in Table 2 indicates that the experimentally determined PSD values for non-micronized DPV form I were slightly larger than the values stated in the certificate of analysis, which may be due to slight differences in the method of analysis or powder sampling protocols. In particular, for larger particle size materials, sampling protocols can have a greater influence on the measured value. After micronization, the particle size distributions for both polymorphs were similar, with an overall tendency towards slightly smaller particles observed for the form IV sample, as evidenced both by the overlap of the distributions (Figure 3B) and the similarity of the values for d₉₀, d₅₀ and d₁₀ (Table 2). The other experimentally determined

particle size distribution values were in good agreement with those specified on the certificates of analysis.

3.3. Powder X-ray diffraction

The X-ray diffraction traces for non-micronized and micronized DPV form I and form IV materials are presented in Figure 4. Both DPV polymorphs are characterised by sharp diffraction peaks confirming the highly crystalline nature of the materials. No significant amorphous content was observed as indicated by the absence of broad peaks and halos. Comparison of traces obtained for the non-micronized and micronized forms of the same polymorph demonstrate a high degree of similarity with regard to peak positions, indicating that the micronization process does not significantly alter the crystal form of either polymorph. However, minor differences in peak intensities were observed, and may be due to a combination of factors including the particle (crystallite) size, orientation of the crystals (preferred or random), amount of powder applied to the background sample holder, or differences in powder packing within the sample holder. Both the non-micronized (Figure 4A) and micronized (Figure 4B) DPV form I diffraction patterns showed significant differences in diffraction peak positions when compared to the form IV materials. In particular, DPV form I traces exhibited distinct diffraction peaks at $2\theta = 5.2^\circ$ and 10.3° not present in the form IV diffraction patterns.

3.4. Microscopy

Representative micrographs of micronized and non-micronized crystals of DPV form I and IV are presented in Figure 5. The non-micronized materials showed large and highly crystalline primary particles in the range of 50–350 μm (Figures 5A and 5B). DPV form IV has a higher proportion of smaller crystals in the $<100\ \mu\text{m}$ range compared to DPV form I, as confirmed by particle size distribution analysis (Figure 3). The micrographs of the micronized DPV materials displayed particles significantly smaller in size (mostly $<10\ \mu\text{m}$). Although the majority of the micronized material was present as small primary particles, some larger agglomerations of particles were also visible.

3.5. Ring appearance and weight

All manufactured rings were free from visible foreign matter and had an off-white opaque appearance consistent with uniform distribution of the white DPV powder throughout the otherwise transparent silicone elastomer matrix. Mean ring weight, ExD and CSD for each form I and form IV ring manufacturing batch ($n=5$ per batch) are recorded in Table 3. All rings had weights $\sim 8.0\ \text{g}$, CSDs $\sim 7.6\ \text{mm}$ and ExDs $\sim 56.4\ \text{mm}$.

3.6. Mechanical Testing

Shore A Hardness measurements, recorded for sample rings from each manufacturing batch and presented in Table 4, are close to 65. The product profile for MED-4870 states a Shore A Hardness value of 70 for samples cured at 165°C (ASTM D2240). The differences observed here are attributed to differences in the cure time temperature profile and the other ingredients included in the formulation, which can have an effect on the mechanical

performance of the silicone elastomer. Although Shore A hardness measurement is commonly used in the rubber industry as a standard indicator of mechanical performance, it is regarded as a basic test and can provide only limited information regarding changes to the mechanical properties of the rings. Since the ring surface is curved, the test performed does not conform to ASTM D2240 or ISO 868:2003 testing standards for shore hardness, which require test specimens to have a flat surface and be at least 6 mm (1/4 in) thick.

Compression testing to measure the maximum force required to compress a ring a distance of 5 mm vertically was also performed for each ring formulation batch (n=5). The results, presented in Figure 6, show that the mean maximum force required for compression of the DPV_(m) form I and form IV rings was similar for all manufacturing batches. No significant batch-to-batch variability between rings of the same formulation was observed. Statistical analysis confirmed that all ring batches tested had statistically similar mechanical properties.

Tensile strength analysis was performed to assess the integrity of the rings on application of a force equivalent to 5 kg. Ten rings of each formulation were analysed. All rings were able to withstand a force equivalent to 5 kg without rupture (data not shown). This arbitrary 5 kg value has been used in the testing of other vaginal ring products (unpublished data). In clinical use, however, vaginal ring devices are not likely to undergo extensive tensile deformation. Therefore, the test is primarily used as a quality performance measure for comparison of different ring formulations and manufacturing processes.

3.7. *In vitro* release

Mean daily and cumulative release versus time plots for both DPV forms I and IV from matrix-type vaginal rings into IPA+H₂O and SVF+Tween media are presented in Figure 7.

The declining daily release values with time (Figures 7A and 7B) are indicative of $t^{1/2}$ kinetics and typical of permeation-controlled drug delivery systems comprising non-biodegradable polymers containing excess solid drug within the matrix.^{20,23,51,52} Daily DPV release values were greater for release into IPA+H₂O compared with SVF+Tween across all time points and for both form I and form IV rings, reflecting the higher solubility of DPV in the solvent/water system. Mean day 1 release values for DPV into IPA+H₂O were 2459 and 2564 μg for form I and IV rings, respectively, decreasing to 191 and 183 μg , respectively, on day 30. Thus, the d1/d30 release ratios for this release medium were 12.9 and 14.0 for form I and IV rings, respectively. Use of SVF+Tween as the release medium produced significantly different (p-value < .00001) day 1 mean release values for the form I and IV rings (349 and 578 μg , respectively), while mean day 30 release values were more similar (116 and 106 μg , respectively; p-value .000019) (Figure 7B); the corresponding d1/d30 release ratios were 3.0 and 5.5, respectively. It is therefore apparent that the SVF+Tween release medium blunts the day 1 *in vitro* release value relative to the day 30 value, compared with the IPA+H₂O release medium. In general, greater variability is observed with the SVF+Tween daily release values compared to those measured using IPA+H₂O, reflecting differences in solvating power between the release media.

Release rates ($\mu\text{g}/\text{day}^{0.5}$) and coefficients of correlation (r^2) obtained from linear regression analysis of the cumulative DPV release vs. root time plots are presented in Table 5.

435

436 Comparing the release between polymorphs reveals that the profiles are similar, with
437 almost identical release into both release media. The only difference of note is increased
438 DPV release over the first three days into SVF+Tween for the form IV polymorph (Figure
439 7B). Since there is no significant difference in SVF+Tween solubility between the
440 polymorphs (Table 6), possible explanations include differences in silicone elastomer
441 solubility between the two forms of DPV, or differences in drug distribution at the surface
442 of the ring devices. Given that much greater variability in drug concentrations are observed
443 in vaginal ring pharmacokinetic studies,^{28,30,53–55} it is highly unlikely that these relatively
444 small differences in *in vitro* release over early timepoints would be clinically significant.

445 Comparing the line equation gradients of the cumulative release lines highlights the small
446 differences observed in terms of the release between different polymorphs. This was
447 confirmed by calculating the similarity factor (f_2) which has been recommended by the
448 FDA for dissolution profile comparison.^{50,56} As the mean cumulative DPV release did not
449 exceed 55% in either case, all of the available release values were included in the
450 calculations. Based on these results, calculated f_2 values were 98.5 for release into
451 IPA+H₂O and 94.9 for release into SVF+Tween, both well above the value of 50 often
452 used to indicate similarity. Interestingly, the *in vitro* cumulative release levels obtained
453 with SVF+Tween over a 30-day period for both the form I and form IV rings were similar
454 to 28-day *in vivo* release levels observed with IPM's 25 mg DPV matrix ring 004 (~4
455 mg).^{33,39} This indicates that the SVF+Tween release media more closely mimics the
456 amount of drug released *in vivo* than either SVF alone or the IPA+H₂O medium.

457

3.8. Content and residual content

Initial dapivirine content in the rings post-manufacture was 24.87 ± 0.16 and 25.82 ± 0.28 mg for rings containing form I and form IV dapivirine, respectively (equivalent to 99.5 and 103.3% of the nominal content value), as measured by a solvent extraction method, and highlighting the consistency of the manufacturing process. Following completion of *in vitro* release testing, all rings were tested for residual dapivirine content. The residual content values were then combined with the cumulative release values and compared to initial ring content values to assess mass balance. The data presented in Table 6 demonstrate almost identical cumulative release between the two polymorphs of 13.1 mg and 4.5 mg into IPA+H₂O and SVF+Tween over 30 days. The amounts of DPV recovered after *in vitro* release testing are also consistent with the slightly higher initial loading in the rings containing form IV DPV compared to those containing form I. Thus, the calculated initial loadings for each polymorph are higher for form IV at approximately 25.8 mg, compared to form I at approximately 25.0 mg. These values fit very well with the initially calculated content values of 25.8 mg and 24.9 mg for form IV and form I respectively.

3.9. DPV solubility

DPV, with an experimental pK_a value of 5.54,⁴⁶ exhibits the typical weak base behaviour of increased solubility as pH is lowered (Figure 8). Moreover, the solubility vs. pH profiles are very similar for polymorphic forms I and IV, within the limits of experimental error. The lower solubility values at pH 1 are due to the common ion effect (i.e. chloride ions) associated with increased concentration of hydrochloric acid. Based on these *in vitro* solubility data, DPV solubility at vaginal pH values typical of women of reproductive age

(typically between 3.5 and 7; the higher values are common with certain vaginal infections and in the presence of semen^{43,57}) would lie within the range 0–15 µg/mL, which goes some way to explaining the wide variation in DPV pharmacokinetics measured in women during ring use.^{14,28,53–55}

Experimentally determined values of thermodynamic solubility for DPV forms I and IV – micronised and non-micronised materials, and measured in both 1:1 v/v IPA/water and SVF+0.2% w/v Tween 80 – are presented in Table 8. As expected, DPV solubility in IPA/water (~1200 µg/mL) is significantly greater (by a factor of ~75) compared with solubility measured in SVF/Tween (~16 µg/mL). That in vitro DPV release from vaginal rings into these two release media does not differ by a similar factor is a consequence of the permeation-controlled release kinetics that apply to silicone elastomer vaginal rings, wherein molecular diffusion of drug through the silicone matrix is rate controlling.⁵¹ The data also clearly illustrate that neither DPV particle size nor the polymorphic form of DPV influence the thermodynamic solubility value, irrespective of the release medium tested. PXRD analysis of the residual DPV material after preparation of saturated solutions confirmed the no form conversion was observed during the solubility analysis and indicating that the results reflect the true solubility of each form (Table 8).

4. Conclusions

This is the first report of the impact of drug polymorphism on the performance characteristics of a vaginal ring device. DPV form I and form IV polymorphs were distinguished using DSC, PXRD and solubility analyses. TGA demonstrated that both

504 polymorphs **were thermally stable** over the range of processing temperatures likely to be
505 encountered during manufacture. Particle size analysis revealed a similar size distribution
506 for micronized versions of both polymorphs whereas the non-micronized form I average
507 particle size was slightly larger than form IV. Manufacture of silicone elastomer rings
508 nominally containing 25 mg DPV produced rings with a mean content with 5% of the
509 nominal value for both polymorphs. *In vitro* release testing of rings showed a very similar
510 release profile for both polymorphs with similarity factor f_2 values greater than 90. An
511 increase in the day 1 to day 3 release for the form IV polymorph compared to the form I
512 polymorph was observed. Possible explanations for this difference include variations in
513 dissolution rates between the two polymorphs and or different surface distributions from
514 manufacture. DPV mass balance was achieved from residual content values plus the
515 cumulative release values recorded into each media. Release of DPV into SVF+Tween
516 over 30 days more closely matches the amount of DPV released *in vivo* over a similar time
517 period than either IPA+H₂O or SVF only. **Finally, no significant differences in**
518 **thermodynamic solubility were observed for the various particle size and polymorphic**
519 **forms of DPV.**

520 **Acknowledgements**

521 The work was supported by a grant to Queen's University Belfast from the International
522 Partnership for Microbicides, through the generous support from the Ministry of Foreign
523 Affairs of the Netherlands and the American people through the United States Agency for
524 International Development (USAID) through the President's Emergency Plan for AIDS
525 Relief (PEPFAR).

526

527 **Declaration of interests**

528 All authors declare no any actual or potential conflicts of interest.

529

530 **Author contribution to manuscript**

531 All authors contributed to the design of the study and drafting of the manuscript for
532 submission. CFM, DJM, PB and KM performed the experimental work. All authors
533 approved submission of the manuscript.

534 **References**

- 535 1. Brittain HG. Polymorphism and Solvatomorphism 2010. *J Pharm Sci.*
536 2012;101(2):464-484. doi:10.1002/jps.22788.
- 537 2. Chemburkar SR, Bauer J, Deming K, et al. Dealing with the Impact of Ritonavir
538 Polymorphs on the Late Stages of Bulk Drug Process Development. *Org Process*
539 *Res Dev.* 2000;4(5):413-417. doi:10.1021/op000023y.
- 540 3. Bauer J, Spanton S, Henry R, et al. Ritonavir: An Extraordinary Case of
541 Conformational Polymorphism. *Pharm Res.* 2001;18(6):859-866.
- 542 4. FDA. Guidance for Industry ANDAs: Pharmaceutical Solid Polymorphism.
543 Evaluation.
544 [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072866.pdf)
545 [/Guidances/ucm072866.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072866.pdf). Published 2007. Accessed December 21, 2016.
- 546 5. International Conference on Harmonisation. Guidance on Q6A Specifications:
547 Test Procedures and Acceptance Criteria for New Drug Substances and New Drug
548 Products: Chemical Substances.
549 [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6A/Step4/Q6Astep4.pdf)
550 [Q6A/Step4/Q6Astep4.pdf](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6A/Step4/Q6Astep4.pdf). Published 1999. Accessed December 21, 2016.
- 551 6. FDA. Draft Guidance on Specifications: Test Procedures and Acceptance Criteria
552 for New Drug Substances and new Drug Products: Chemical Substances.
553 [http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm134966.htm)
554 [/ucm134966.htm](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm134966.htm). Published 2000. Accessed December 21, 2016.
- 555 7. das Neves J, Martins JP, Sarmento B. Will dapivirine redeem the promises of anti-
556 HIV microbicides? Overview of product design and clinical testing. *Adv Drug*
557 *Deliv Rev.* 2016;103:20-32. doi:10.1016/j.addr.2015.12.015.
- 558 8. D'Cruz OJ, Uckun FM, Cruz OJD, Uckun FM. Dawn of non-nucleoside inhibitor-
559 based anti-HIV microbicides. *J Antimicrob Chemother.* 2006;57(3):411-423.
560 doi:10.1093/jac/dki464.
- 561 9. Di Fabio S, Van Roey J, Giannini G, et al. Inhibition of vaginal transmission of
562 HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor
563 TMC120 in a gel formulation. *AIDS.* 2003;17(11):1597-1604.
564 doi:10.1097/01.aids.0000072663.21517.63.
- 565 10. Fletcher P, Harman S, Azijn H, et al. Inhibition of human immunodeficiency virus
566 type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse
567 transcriptase inhibitor. *Antimicrob Agents Chemother.* 2009;53(2):487-495.
568 doi:10.1128/AAC.01156-08.
- 569 11. Van Herrewege Y, Michiels J, Van Roey J, et al. In vitro evaluation of
570 nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as
571 human immunodeficiency virus microbicides. *Antimicrob Agents Chemother.*
572 2004;48(1):337-339. doi:10.1128/AAC.48.1.337.
- 573 12. Van Herrewege Y, Vanham G, Michiels J, et al. A series of diaryltriazines and

- diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides. *Antimicrob Agents Chemother*. 2004;48(10):3684-3689. doi:10.1128/AAC.48.10.3684-3689.2004.
13. Akil A, Parniak MA, Cost MR, et al. Development and Characterization of a Vaginal Film Containing Dapivirine, a Non- nucleoside Reverse Transcriptase Inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. *Drug Deliv Transl Res*. 2011;1(3):209-222. doi:10.1007/s13346-011-0022-6.
 14. Nel AM, Coplan P, Smythe SC, et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. *AIDS Res Hum Retroviruses*. 2010;26(11):1181-1190. doi:10.1089/aid.2009.0227.
 15. Nel AM, Smythe SC, Habibi S, Kaptur PE, Romano JW. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel. *J Acquir Immune Defic Syndr*. 2010;55(2):161-169. doi:10.1097/QAI.0b013e3181e3293a.
 16. Major I, Boyd P, Kilbourne-brook M, Saxon G, Cohen J, Malcolm RK. A modified SILCS contraceptive diaphragm for long-term controlled release of the HIV microbicide dapivirine. *Contraception*. 2013;88(1):58-66. doi:10.1016/j.contraception.2012.10.018.
 17. Woolfson AD, Umrethia ML, Kett VL, Malcolm RK. Freeze-dried, mucoadhesive system for vaginal delivery of the HIV microbicide, dapivirine: optimisation by an artificial neural network. *Int J Pharm*. 2010;388(1-2):136-143. doi:10.1016/j.ijpharm.2009.12.042.
 18. das Neves J, Araújo F, Andrade F, Amiji M, Bahia MF, Sarmiento B. Biodistribution and Pharmacokinetics of Dapivirine-Loaded Nanoparticles after Vaginal Delivery in Mice. *Pharm Res*. January 2014. doi:10.1007/s11095-013-1287-x.
 19. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, Mccullagh SD. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. *J Antimicrob Chemother*. 2005;56(5):954-956. doi:10.1093/jac/dki326.
 20. Boyd P, Fetherston SM, Mccoy CF, et al. Matrix and reservoir-type multipurpose vaginal rings for controlled release of dapivirine and levonorgestrel. *Int J Pharm*. 2016;511(1):619-629. doi:10.1016/j.ijpharm.2016.07.051.
 21. Nel A, Kapiga S, Bekker L-G, Devlin B, Borremans M, Rosenberg Z. Safety and Efficacy of Dapivirine Vaginal Ring for HIV-1 Prevention in African Women. In: *Conference on Retroviruses and Opportunistic Infections*. Boston; 2016:110LB.
 22. Devlin B, Nuttall J, Wilder S, Woodsong C, Rosenberg Z. Development of dapivirine vaginal ring for HIV prevention. *Antiviral Res*. 2013;100 Suppl(SUPPL.):S3-8. doi:10.1016/j.antiviral.2013.09.025.
 23. Fetherston SM, Boyd P, McCoy CF, et al. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. *Eur J Pharm Sci*. 2013;48(3):406-415. doi:10.1016/j.ejps.2012.12.002.

24. Malcolm RK, Boyd PJ, McCoy CF, Murphy DJ. Microbicide vaginal rings: Technological challenges and clinical development. *Adv Drug Deliv Rev.* 2015;103:33-56. doi:10.1016/j.addr.2016.01.015.
25. Murphy DJ, Desjardins D, Dereuddre-Bosquet N, et al. Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir. *J Antimicrob Chemother.* 2014;(i):1-12. doi:10.1093/jac/dku160.
26. Murphy DJ, Boyd P, McCoy CF, et al. Controlling levonorgestrel binding and release in a multi-purpose prevention technology vaginal ring device. *J Control Release.* 2016;226:138-147. doi:10.1016/j.jconrel.2016.02.020.
27. Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. *N Engl J Med.* 2016;NEJMoa1506110. doi:10.1056/NEJMoa1506110.
28. Nel A, Smythe S, Young K, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. *J Acquir Immune Defic Syndr.* 2009;51(4):416-423.
29. Malcolm RK, Fetherston SM, McCoy CF, Boyd P, Major I. Vaginal rings for delivery of HIV microbicides. *Int J Womens Health.* 2012;4:595-605. doi:10.2147/IJWH.S36282.
30. Nel AM, Haazen W, Nuttall JP, et al. Pharmacokinetics and Safety Assessment of Anti-HIV Dapivirine Vaginal Microbicide Rings with Multiple Dosing. *J AIDS Clin Res.* 2014;5(10):1000355. doi:10.4172/2155-6113.1000355.
31. Woolfson AD, Malcolm RK, Morrow RJ, Toner CF, McCullagh SD. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. *Int J Pharm.* 2006;325(1-2):82-89. doi:10.1016/j.ijpharm.2006.06.026.
32. Bell SEJ, Dennis AC, Fido LA, et al. Characterization of silicone elastomer vaginal rings containing HIV microbicide TMC120 by Raman spectroscopy. *J Pharm Pharmacol.* 2007;59(2):203-207. doi:10.1211/jpp.59.2.0007.
33. Nel A, van Niekerk N, Kapiga S, et al. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women. *N Engl J Med.* 2016;375(22):2133-2143. doi:10.1056/NEJMoa1602046.
34. MacQueen KM, Weaver MA, van Loggerenberg F, et al. Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study. *AIDS Behav.* 2014;18(5):826-832. doi:10.1007/s10461-014-0753-8.
35. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. *Science.* 2010;329(5996):1168-1174. doi:10.1126/science.1193748.
36. Kashuba ADM, Gengiah TN, Epi MS, et al. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial : Importance of Adherence for Microbicide Effectiveness. 2015;69(3):264-269.
37. Mauck CK, Straten A van der. Using objective markers to assess participant behavior in HIV prevention trials of vaginal microbicides. *J Acquir Immune Defic*

- 658 *Syndr.* 2008;49(1):64-69. doi:10.1097/QAI.0b013e318183a917.
- 659 38. Minnis AM, Straten A Van Der, Salee P. Pre-exposure Prophylaxis Adherence
660 Measured by Plasma Drug Level in MTN-001 : Comparison Between Vaginal Gel
661 and Oral Tablets in Two Geographic Regions. *AIDS Behav.* 2015.
662 doi:10.1007/s10461-015-1081-3.
- 663 39. Spence P, Nel A, van Niekerk N, Derrick T, Wilder S, Devlin B. Post-Use Assay
664 of Vaginal Rings (VRs) as a Potential Measure of Clinical Trial Adherence. *J*
665 *Pharm Biomed Anal.* 2016;125:94-100. doi:10.1016/j.jpba.2016.03.023.
- 666 40. Stalter RM, Moench TR, MacQueen KM, Tolley EE, Owen DH, Consortium for
667 Ring Adherence. Biomarkers and biometric measures of adherence to use of ARV-
668 based vaginal rings. *J Int AIDS Soc.* 2016;19(1):20746.
669 doi:10.7448/IAS.19.1.20746.
- 670 41. Tolley EE, Harrison PF, Goetghebeur E, et al. Adherence and its measurement in
671 phase 2/3 microbicide trials. *AIDS Behav.* 2010;14(5):1124-1136.
672 doi:10.1007/s10461-009-9635-x.
- 673 42. Amico KR, Mansoor LE, Corneli A, Torjesen K, Van Der Straten A. Adherence
674 support approaches in biomedical HIV prevention trials: Experiences, insights and
675 future directions from four multisite prevention trials. *AIDS Behav.*
676 2013;17(6):2143-2155. doi:10.1007/s10461-013-0429-9.
- 677 43. Owen DH, Katz DF. A vaginal fluid simulant. *Contraception.* 1999;59(2):91-95.
- 678 44. FDA. Guidance for Industry Vaginal Microbicides : Development for the
679 Prevention of HIV Infection Guidance for Industry Vaginal Microbicides :
680 Development for the Prevention of HIV Infection.
681 <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM328842.pdf>. Published 2014.
682
- 683 45. Malcolm RK, Veazey RS, Geer L, et al. Sustained release of the CCR5 inhibitors
684 CMPD167 and maraviroc from vaginal rings in rhesus macaques. *Antimicrob*
685 *Agents Chemother.* 2012;56(5):2251-2258. doi:10.1128/AAC.05810-11.
- 686 46. Fetherston SM, Geer L, Veazey RS, et al. Partial protection against multiple RT-
687 SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal
688 ring releasing the NNRTI MC1220. *J Antimicrob Chemother.* 2013;68(2):394-403.
689 doi:10.1093/jac/dks415.
- 690 47. Murphy DJ, Amssoms K, Pille G, et al. Sustained release of the candidate
691 antiretroviral peptides T-1249 and JNJ54310516-AFP from a rod insert vaginal
692 ring. 2016. doi:10.1007/s13346-015-0273-8.
- 693 48. Nel A, van Niekerk N, Kapiga S, et al. Safety and Efficacy of a Dapivirine Vaginal
694 Ring for HIV Prevention in Women. *N Engl J Med.* 2016;375(22):2133-2143.
695 doi:10.1056/NEJMoa1602046.
- 696 49. Moore JW, Flanner HH. Moore JW Pharm Tech 1996.pdf. *Pharm Technol.*
697 1996;20(6):64-74.
- 698 50. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. *Eur J*
699 *Pharm Sci.* 2001;13(2):123-133. doi:10.1016/S0928-0987(01)00095-1.

51. Malcolm K, Woolfson D, Russell J, Tallon P, Mcauley L, Craig D. Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. *J Control Release*. 2003;90(2):217-225.
52. Malcolm RK, Boyd PJ, McCoy CF, Murphy DJ. Microbicide vaginal rings: Technological challenges and clinical development. *Adv Drug Deliv Rev*. 2016;103:33-56. doi:10.1016/j.addr.2016.01.015.
53. Nel A, Haazen W, Nuttall J, Romano J, Rosenberg Z, van Niekerk N. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. *AIDS*. March 2014;1. doi:10.1097/QAD.0000000000000280.
54. Romano J, Variano B, Coplan P, et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. *AIDS Res Hum Retroviruses*. 2009;25(5):483-488. doi:10.1089/aid.2008.0184.
55. Chen BA, Panther L, Marzinke MA, et al. Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. *J Acquir Immune Defic Syndr*. 2015;70(3):242-249. doi:10.1097/QAI.0000000000000702.
56. Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison-Statistics and analysis of the similarity factor, f2. *Pharm Res*. 1998;15(6):889-896. doi:10.1023/A:1011976615750.
57. Fox C, Meldrum S, Watson B. Continuous measurement of pH by radio-telemetry of vaginal pH during human coitus. *J Reprod Fertil*. 1973;33(1940):69-75.

722

723

724

725 **Figure 1.** Summary of the relationships between the crystalline and amorphous
 726 polymorphic forms of dapivirine. DCM = dichloromethane. Forms I and IV were
 727 characterized by thermogravimetric analysis (TGA), differential scanning calorimetry
 728 (DSC), polarized light microscopy, hot stage microscopy, x-ray powder diffraction
 729 (XRPD), variable temperature XRPD (VT-XRPD) and single crystal x-ray diffraction.
 730 Both forms were also tested by gravimetric vapour sorption (GVS) to assess
 731 hygroscopicity, as well as solubility in common aqueous and organic solvents.
 732 [Unpublished data; IPM].

Figure 2. Representative DSC traces of non-micronized DPV (A) form I and (B) form IV. For clarity, heat flow values between -0.4 and 0.4 are displayed, such that some peaks are truncated. Values of the enthalpies associated with each endotherm and exotherm are presented in Table 1. The second heat cycle for form IV has been offset by -0.1 W/g to aid visualisation.

739

740 **Figure 3.** Measured particle size distribution of DPV form I and form IV. (A) non-
 741 micronized powders; (B) micronized powders.

Figure 4. Powder XRD traces for (A) non-micronized DPV form I, (B) micronized DPV form I, (C) non-micronized DPV form IV, and (D) micronized DPV form IV. Data is presented in the 2θ angular range of 3 to 50° . Two peaks in A, at $2\theta = 5.2$ and 10.3 degrees, have been truncated to allow better comparison of the traces.

Figure 5. Representative micrographs recorded at 200x magnification of non-micronized DPV form I (A), form IV (B), and micronized DPV form I (C) and form IV (D).

753

754 **Figure 6.** Mean maximum force required to compress each ring formulation (n=5 per batch).

Figure 7. Mean daily release versus time profiles for release into (A) IPA+H₂O and (B) SVF+Tween, and cumulative release versus root time profiles for release into (C) IPA+H₂O and (D) SVF+Tween, of DPV from MED-4870 matrix-type vaginal rings containing DPV (either form I or form IV, 25 mg per ring) over 30 days. Error bars in graphs A and B represent standard deviation of twelve replicates; error bars were often smaller than the plot symbol. A small deviation from the otherwise very consistent drug release profile is present on day 22 of the release into SVF+Tween (B and D). This was due to an extended weekend release period without replacement of release medium.

Figure 8. pH versus solubility profiles for DPV forms I and IV. Plot symbols represent the mean of four replicates; error bars representing $\pm$ standard deviation are smaller than the plot symbols.

Table 1. Mean peak onset temperature (°C), peak temperature (°C) and enthalpy (ΔH , J/g) values for each thermal transition associated with micronized and non-micronized DPV forms I and IV. Endothermic transitions 1 & 2 are observed during the 1st heat cycle, endothermic transitions 3 & 5 and exothermic transition 4 are observed during the 2nd heat cycle.

DPV material *	Transition No.	Onset (°C)	Peak Maximum (°C)	Enthalpy (ΔH , J/g)	Assignment
form I _(m)	1	101.1	104.1	8.0	I→II
form I _(nm)	1	97.8	99.3	10.4	I→II
form IV _(nm)	1	205.8	209.3	10.9	IV→II
form IV _(m)	1	189.4	199.0	8.0	IV→II
form I _(m)	2	219.9	221.9	114.7	II melting
form I _(nm)	2	219.9	221.9	119.2	
form IV _(nm)	2	220.0	221.8	121.9	
form IV _(m)	2	220.1	221.8	104.2	
form I _(m)	3	80.9	85.6	1.6	T _g with amorphous relaxation
form I _(nm)	3	80.9	85.5	1.8	
form IV _(nm)	3	81.2	85.6	1.4	
form IV _(m)	3	81.2	85.7	1.6	
form I _(m)	4	163.0	167.9	-82.9	Recrystallization to form II
form I _(nm)	4	159.8	167.4	-87.4	
form IV _(nm)	4	154.4	163.0	-87.4	
form IV _(m)	4	153.8	164.8	-68.4	
form I _(m)	5	219.6	221.9	112.8	II melting
form I _(nm)	5	219.5	221.7	117.0	
form IV _(nm)	5	219.7	221.9	118.1	
form IV _(m)	5	219.8	221.9	100.2	

* nm – non-micronized, m – micronized

Table 2. Experimentally determined d_{90} , d_{50} and d_{10} values for both non-micronized and micronized DPV form I and form IV materials with comparative certificate of analysis values where available.

DPV Batch *	Experimentally Determined Particle Size (μm)			CoA [#] Specified Particle Size (μm)		
	d_{90}	d_{50}	d_{10}	d_{90}	d_{50}	d_{10}
form I _(nm)	324	111	22.1	302	101	19
form I _(m)	14.7	6.00	2.20	14.0	5.9	2.0
form IV _(nm)	250	74.4	17.8	N/A	N/A	N/A
form IV _(m)	14.5	5.00	1.58	14.6	4.82	0.55

* nm – non-micronized, m – micronized; [#] CoA – certificate of analysis

Table 3. Mean ring weight, external diameter and cross-sectional diameter for five rings assessed from each micronized DPV manufacturing batch.

DPV polymorph (Batch No.)	Ring Weight (Mean $\pm$ SD; g)	C.S.D. (Mean $\pm$ SD; mm)	Mean Ex.D. $\pm$ SD (mm)
form I (B1)	7.93 $\pm$ 0.24	7.58 $\pm$ 0.10	56.41 $\pm$ 0.04
form I (B2)	7.99 $\pm$ 0.01	7.62 $\pm$ 0.01	56.41 $\pm$ 0.03
form IV (B1)	7.99 $\pm$ 0.06	7.62 $\pm$ 0.01	56.39 $\pm$ 0.02
form IV (B2)	8.05 $\pm$ 0.01	7.62 $\pm$ 0.02	56.39 $\pm$ 0.02

B1 – batch 1, B2 – batch 2; acceptable limits for weight (7.2 – 8.8 g), external diameter (Ex.D.; 54.9 – 57.1 mm) and cross sectional diameter (C.S.D.; 7.3 – 8.1 mm).

Table 4. Mean Shore A hardness measurement for five rings assessed from each micronized DPV manufacturing batch.

Batch Details	Shore A Hardness $\pm$ SD (arbitrary units)
DPV form I (B1)	64.9 $\pm$ 1.0
DPV form I (B2)	65.1 $\pm$ 0.5
DPV form IV (B1)	65.1 $\pm$ 0.3
DPV form IV (B2)	65.7 $\pm$ 0.2

B1 – batch 1, B2 – batch 2

Table 5. Release rates and coefficients of correlation (r^2) obtained from linear regression analysis of the cumulative DPV release vs. root time plots for matrix-type vaginal rings containing different forms of micronized DPV released into IPA+H₂O or SVF+Tween.

DPV type	Release medium	Release rate ($\mu\text{g/day}^{0.5}$)	r^2 value
form I	IPA+H ₂ O	2330	0.9983
form IV	IPA+H ₂ O	2323	0.9980
form I	SVF+Tween	959.9	0.9823
form IV	SVF+Tween	887.8	0.9880
form I	SVF+Tween (day 8-30)	1146.4	0.9993
form IV	SVF+Tween (day 8-30)	1027.5	0.9995

Table 6. Thermodynamic solubility values for DPV forms I and IV, micronized and non-micronized, into SVF + 0.2% Tween 80 and 1:1 v/v IPA/water. Both release media have been used routinely throughout the development process for the DPV-releasing vaginal ring. Solubility values are reported as mean $\pm$ SD of n=4 replicates.

DPV polymorph	Solvent system	DPV solubility at 37 °C (Mean $\pm$ SD; μ g/mL)	PXRD analysis of residual solid
form I _(nm)	SVF + 0.2% (w/v) Tween 80	16.78 $\pm$ 0.66	form I
form I _(m)	SVF + 0.2% (w/v) Tween 80	16.12 $\pm$ 0.29	form I
form I _(nm)	IPA/water (1:1 v/v)	1171 $\pm$ 53	form I
form I _(m)	IPA/water (1:1 v/v)	1249 $\pm$ 46	form I
form IV _(nm)	SVF + 0.2% (w/v) Tween 80	14.74 $\pm$ 0.99	form IV
form IV _(m)	SVF + 0.2% (w/v) Tween 80	15.83 $\pm$ 0.14	form IV
form IV _(nm)	IPA/water (1:1 v/v)	1193 $\pm$ 36	form IV
form IV _(m)	IPA/water (1:1 v/v)	1214 $\pm$ 34	form IV

Table 7. Amount of DPV released, residual DPV content and calculated initial content values for 25 mg (nominally) DPV polymorph rings.

DPV polymorph	Release medium	DPV released (mg)	Residual DPV (mg)	Calculated initial DPV content (mg)
form I	IPA+H ₂ O	13.1 ± 0.2	12.0 ± 0.3	25.1 ± 0.4
form IV	IPA+H ₂ O	13.1 ± 0.5	12.6 ± 0.3	25.7 ± 0.3
form I	SVF+Tween	4.6 ± 0.1	20.3 ± 0.4	24.9 ± 0.3
form IV	SVF+Tween	4.5 ± 0.4	21.3 ± 0.4	25.9 ± 0.5